Alpha-1 antitrypsin replacement therapy - Celon Pharma
Latest Information Update: 26 Apr 2023
At a glance
- Originator Celon Pharma
- Class RNA
- Mechanism of Action Alpha 1-antitrypsin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alpha 1-antitrypsin deficiency
Most Recent Events
- 28 Mar 2023 Early research in Alpha 1-antitrypsin deficiency in Poland (Parenteral) (Celon Pharma Pipeline, March 2023)